Pamela Kryskow
Clinical Instructor, Faculty of Medicine at the University of British Columbia; Adjunct Professor at Vancouver Island University; Medical Lead at Roots to Thrive
Data updated
Research Footprint
Pamela Kryskow appears in 5 tracked papers (2021–2023), most studied alongside Psilocybin, MDMA and LSD, across Microdosing, Anxiety Disorders and Depressive Disorders.
Most-cited paper: Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers (75 citations).
Frequent co-authors: Kim Kuypers, Zachary Walsh and Kalin Harvey.
Background & Research
Dr. Pamela Kryskow is a medical doctor and researcher in psychedelic medicine with a focus on mental health, chronic pain, and clinical applications of psychedelics. She serves as Medical Lead for Roots to Thrive and is involved in teaching and program leadership at Vancouver Island University and the University of British Columbia. Her work includes studies on microdosing, psilocybin, MDMA-assisted therapy, and pain outcomes.
Key Impact
She is a physician-researcher contributing to clinical and observational research on psychedelic-assisted therapy, microdosing, and chronic pain, helping build the evidence base for emerging psychedelic medicine.
Collaboration Network
10 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Pamela Kryskow is associated with.
Vancouver Island University
academicIn response to the fallout from the COVID-19 pandemic, a research group at Vancouver Island University (VIU) has been awarded funding from the Canadian Institutes of Health Research for the exploration of psychedelic therapies for front-line workers. Led by Dr Shannon Dames, the team are currently focusing on ketamine-assisted therapy for front-line workers experiencing symptoms of PTSD and emotional distress as a result of their experiences working through the pandemic.
View stakeholder →Numinus Wellness
Public BiotechCanadian company providing clinical research services and therapist training for psychedelic-assisted therapies. Originally a psychedelic clinic operator, Numinus divested its US clinic assets in 2024 and reoriented as a contract research organisation (CRO) and training provider. Health Canada licensed to produce and analyse psilocybin.
View stakeholder →MycoMedica Life Sciences
Public Benefit CorpMycoMedica Life Sciences PBC is a public benefit corporation developing low-dose psilocybin medicines for psychiatric and neurological disorders. Their lead candidate MLS101 is in Phase 1 clinical development, with PMDD as the lead indication and OUD and OCD as additional targets. Based in Shelton, Washington.
View stakeholder →